Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Walmart, CVS to halt filling prescriptions for controlled substances by Cerebral, Done

Published 05/25/2022, 08:29 PM
Updated 05/26/2022, 07:16 PM
© Reuters. FILE PHOTO: A Walmart sign is pictured at one of their stores in Mexico City, Mexico March 28, 2019. REUTERS/Edgard Garrido

(Reuters) -Walmart Inc and CVS Health Corp (NYSE:CVS) said on Wednesday they would stop filling prescriptions for controlled substances issued by telehealth startups Cerebral Inc and Done Health.

Cerebral and Done are known for treating patients with ADHD, prescribing stimulants such as Adderall.

Walmart (NYSE:WMT) confirmed the move to Reuters and said the decision was made after an audit and compliance process.

CVS said it would not accept prescriptions for controlled substances issued by the startups effective May 26, as a result of a review it conducted on the telehealth firms and after it was "unable to resolve concerns we have with Cerebral and Done Health."

Cerebral had earlier this month decided to stop prescribing controlled substances and taper existing prescriptions based on the impending expiration of waivers, the company said in an emailed statement.

The company was working to ensure that existing patients with controlled substance prescriptions are able to receive their medications, while working with the pharmacies to allow sufficient time to adjust to the changes, Cerebral said.

Cerebral said it plans to continue to prescribe controlled substances to treat opioid use disorder.

Done Health also said it would continue to provide prescriptions for psychiatric chronic care management.

© Reuters. FILE PHOTO: A Walmart sign is pictured at one of their stores in Mexico City, Mexico March 28, 2019. REUTERS/Edgard Garrido

"We expect this situation will be quickly resolved, if provided the opportunity, so patients can access the medications they have been prescribed using evidence based medicine," Done Health said on Thursday.

According to a Wall Street Journal report https://on.wsj.com/3MNn01f earlier this month, Cerebral had been issued a subpoena by federal prosecutors as part of an investigation into possible violations of the Controlled Substances Act.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.